Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea.
Cornea. 2020 Feb;39(2):234-236. doi: 10.1097/ICO.0000000000002096.
To measure changes in the matrix metalloproteinase 9 (MMP-9) point-of-care test, InflammaDry (Rapid Pathogen Screening, Inc, Sarasota, FL) positivity, based on ocular surface MMP-9 concentrations and loading volume.
Two different MMP-9 products, preform and active, were analyzed using the InflammaDry test, detecting MMP-9 levels of more than 40 ng/mL of both preform and active MMP-9. Preform MMP-9 (Natural human MMP-9 protein; Abcam, Cambridge, UK) was analyzed at different concentrations (50, 100, 500, 1000, and 1500 ng/mL) and loading volumes (5, 10, and 20 μL). Active MMP-9 (Human MMP-9 protein; Novus Biologicals, Littleton, CO) was also analyzed using the InflammaDry test at different concentrations (50 and 100 ng/mL) and loading volumes (10, 20, and 40 μL).
Natural human MMP-9 protein (preform) of 50, 100, and 500 ng/mL exhibited negative results for every loading volume. At 1000 ng/mL, the 20 μL volume was positive, whereas the 5 and 10 μL volumes were negative. At 1500 ng/mL, all loading volumes were positive, but the density of positive bands varied depending on the loading volume; larger loading volumes had higher band density. Human MMP-9 protein (active) of 50 ng/mL was negative for every loading volume. In 100 ng/mL, the 20 and 40 μL volumes showed positive results with similar positive band densities.
The InflammaDry test had a different detection range depending on MMP-9 formulas; higher concentrations of preform MMP-9 protein were needed to yield positive results. In addition, InflammaDry positivity varied based on the loading volumes. Clinicians should be aware of the possibility of false negatives with low tear volumes despite elevated MMP-9 concentrations.
基于眼表基质金属蛋白酶 9（MMP-9）浓度和加载量，测量即时护理检测（Point-of-Care Test，POCT）中基质金属蛋白酶 9（MMP-9）的变化，即InflammaDry（Rapid Pathogen Screening，Inc，佛罗里达州萨拉索塔）阳性率。
采用即时护理检测（InflammaDry test）分别对两种不同的 MMP-9 产品（前体和活性）进行分析，检测前体和活性 MMP-9 均超过 40ng/ml。分析不同浓度（50、100、500、1000 和 1500ng/ml）和加载量（5、10 和 20μl）的前体 MMP-9（天然人 MMP-9 蛋白；Abcam，英国剑桥）。还使用即时护理检测（InflammaDry test）分析不同浓度（50 和 100ng/ml）和加载量（10、20 和 40μl）的活性 MMP-9（人 MMP-9 蛋白；Novus Biologicals，科罗拉多州利特尔顿）。
浓度为 50、100 和 500ng/ml 的天然人 MMP-9 蛋白（前体）在每个加载量下均呈阴性。在 1000ng/ml 时，20μl 体积呈阳性，而 5μl 和 10μl 体积呈阴性。在 1500ng/ml 时，所有加载量均为阳性，但阳性条带的密度取决于加载量；较大的加载量具有更高的条带密度。浓度为 50ng/ml 的人 MMP-9 蛋白（活性）在每个加载量下均呈阴性。在 100ng/ml 时，20μl 和 40μl 体积的结果均为阳性，阳性条带密度相似。
即时护理检测（InflammaDry test）根据 MMP-9 公式具有不同的检测范围；需要更高浓度的前体 MMP-9 蛋白才能产生阳性结果。此外，即时护理检测（InflammaDry test）的阳性率因加载量而异。临床医生应注意尽管 MMP-9 浓度升高，但由于泪液体积低，仍可能出现假阴性。
